Diabetes Stem Cell Therapy Market Report 2026

The diabetes stem cell therapy market size has grown rapidly in recent years. It will grow from $3.01 billion in 2025 to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to rising prevalence of type 1 and type 2 diabetes, early-stage success of stem cell research programs, growth of regenerative medicine funding, increasing clinical trial activity, expanding academic research collaborations.

The diabetes stem cell therapy market size is expected to see rapid growth in the next few years. It will grow to $5.29 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expansion of advanced clinical trials, increasing regulatory approvals for cell therapies, rising investment from pharmaceutical companies, growing adoption of personalized regenerative treatments, technological progress in scalable cell manufacturing. Major trends in the forecast period include increasing development of beta cell replacement therapies, rising focus on immune modulation approaches, expansion of allogeneic stem cell platforms, growing use of encapsulation technologies, advancement of gene-modified stem cell solutions.

The growing need for novel treatments is expected to drive growth in the diabetes stem cell therapy market going forward. Novel treatments refer to therapies that use new mechanisms, targets, or approaches not previously available for disease management. This demand is fueled by the rising prevalence of complex and chronic diseases, as conventional therapies often fail to provide effective or long-term solutions. Diabetes stem cell therapy supports these novel treatments by offering regenerative approaches that can restore pancreatic function, reduce dependence on insulin, and potentially provide long-term cures for diabetes. For instance, in January 2025, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, 1,035 new drugs were approved, of which 337 were novel drugs, including 81 first-in-class therapies, accounting for 24% of the novel approvals. Therefore, the growing need for novel treatments is driving the diabetes stem cell therapy market.

Companies in the diabetes stem cell therapy market are focusing on innovations in biotechnology, stem cell research, and regenerative medicine to develop cellular therapies that restore insulin production and improve glycemic control in patients with type 1 diabetes. These technologies use living cells, tissues, and molecular techniques to repair, replace, or regenerate damaged organs or cells, offering advanced solutions for chronic diseases. For instance, in June 2023, CellTrans Inc., a US-based biotechnology company, received FDA approval for Lantidra, the first allogeneic pancreatic islet cellular therapy derived from deceased donor pancreatic cells for adults with type 1 diabetes experiencing recurrent severe hypoglycemia. Lantidra is administered via a single infusion into the hepatic portal vein, where transplanted islet beta cells secrete insulin, enabling some patients to achieve insulin independence for one year or more, with cases extending up to five years, significantly improving disease management, quality of life, and glycemic control.

The diabetes stem cell therapy market is also seeing growth through strategic acquisitions. In June 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Sigilon Therapeutics Inc. for $309.6 million. Through this acquisition, Eli Lilly strengthened its capabilities in encapsulated cell-therapy solutions for type 1 diabetes by integrating Sigilon’s shielded-cell technology into its portfolio. Sigilon Therapeutics Inc. is a US-based biopharmaceutical company developing stem cell-based therapies for type 1 diabetes.

Major companies operating in the diabetes stem cell therapy market are Mesoblast Limited, Swiss Medica Stem Cells SA, Aspect Biosystems Ltd., Celltex Therapeutics Corporation, Seraxis Inc., BrainStorm Cell Therapeutics Inc., Sernova Corporation, Betalin Therapeutics Ltd., NextCell Pharma AB, PharmaCyte Biotech Inc., Global Institute for Stem Cell Therapy and Research, Throne Biotechnologies Inc., Orgenesis Inc., Holostem Terapie Avanzate S.r.l., Anterogen Co. Ltd., Juventa Regenerative Medicine Inc., Cytori Therapeutics Inc., Pluristem Therapeutics Inc., ReNeuron Group Plc, Athersys Inc.

North America was the largest region in the diabetes stem cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes stem cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetes stem cell therapy market by increasing costs of imported laboratory equipment, bioprocessing consumables, cell culture media, cryopreservation systems, and precision manufacturing tools used in preclinical and clinical research. North America and Europe are most affected due to dependence on specialized imported life science equipment, while Asia-Pacific faces higher costs for advanced research materials. These tariffs are raising research and development expenditures and slowing clinical trial timelines. However, they are also encouraging domestic manufacturing of bioprocessing inputs, regional supply chain localization, and increased investment in local cell therapy infrastructure.

The diabetes stem cell therapy market research report is one of a series of new reports that provides diabetes stem cell therapy market statistics, including diabetes stem cell therapy industry global market size, regional shares, competitors with a diabetes stem cell therapy market share, detailed diabetes stem cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes stem cell therapy industry. This diabetes stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes stem cell therapy is a medical approach that uses stem cells to treat or manage diabetes by regenerating, repairing, or replacing damaged pancreatic cells, especially insulin-producing beta cells. It is applied in clinical research and regenerative medicine to improve blood glucose control, reduce diabetes-related complications, and potentially provide long-term disease management.

The main types in the diabetes stem cell therapy market are preclinical therapies and clinical phase 1 and 2 therapies. Preclinical therapies are experimental treatments tested in laboratories or animal models to evaluate safety, efficacy, and therapeutic potential before human trials. These therapies include autologous, allogeneic, induced pluripotent, mesenchymal, and hematopoietic stem cell approaches, delivered via intravenous injection, intramuscular injection, intra-pancreatic injection, or local tissue delivery. Applications include treatment of type 1 diabetes, management of type 2 diabetes, therapy for diabetic complications, and islet cell transplantation. The primary end users are hospitals, research institutes, diabetes clinics, and pharmaceutical companies.

The diabetes stem cell therapy market consists of revenues earned by entities by providing services such as stem cell transplantation services, quality control testing, logistics and cryopreservation services, and patient monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes stem cell therapy market also includes sales of bioreactors, syringes, cell therapy kits, diagnostic kits, and laboratory consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.